Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE-ESCC: Total Neoadjuvant Therapy for Locally Advanced ESCC
NCT06764355Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06764355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764355.